Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Ho Website

Mitchell Ho, Ph.D.

Selected Publications

1)  Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M.
A binding domain on mesothelin for CA125/MUC16.
J. Biol. Chem. 284: 3739-49, 2009.
2)  Phung Y, Gao W, Man YG, Nagata S, Ho M.
High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
MAbs. 4: 592-9, 2012.
3)  Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, Ho M.
A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.
Mol. Cancer Ther. 12: 416-26, 2013.
4)  Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M.
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
Proc. Natl. Acad. Sci. U.S.A. 110: E1083-91, 2013.
5)  Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, Ho M.
Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Hepatology. [Epub ahead of print], 2014.
6)  Feng M, Ho M.
Glypican-3 antibodies: a new therapeutic target for liver cancer.
FEBS Lett. 588: 377-82, 2014.
7)  Kim H, Gao W, Ho M.
Novel Immunocytokine IL12-SS1 (Fv) Inhibits Mesothelioma Tumor Growth in Nude Mice.
PLoS ONE. 8: e81919, 2013.
8)  Gauthier A, Ho M.
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update.
Hepatol. Res. 43: 147-54, 2013.
9)  Tang Z, Qian M, Ho M.
The role of mesothelin in tumor progression and targeted therapy.
Anticancer Agents Med Chem. 13: 276-80, 2013.
10)  Ho M, Royston I, Beck A.
2 (nd) PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.
MAbs. 4: 562-70, 2012.
11)  Kim H, Phung Y, Ho M.
Changes in Global Gene Expression Associated with 3D Structure of Tumors: An Ex Vivo Matrix-Free Mesothelioma Spheroid Model.
PLoS ONE. 7: e39556, 2012.
12)  Kalra N, Zhang J, Yu Y, Ho M, Merino M, Cao L, Hassan R.
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Int. J. Cancer. 131: 2143-52, 2012.
13)  Ho M, Feng M, Fisher RJ, Rader C, Pastan I.
A novel high-affinity human monoclonal antibody to mesothelin.
Int. J. Cancer. 128: 2020-30, 2011.
14)  Ho M.
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.
BioDrugs. 25: 275-84, 2011.
15)  Ho M, Kim H.
Glypican-3: a new target for cancer immunotherapy.
Eur. J. Cancer. 47: 333-8, 2011.
16)  Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, Takayama S.
High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array.
Analyst. 136: 473-8, 2011.
17)  Xiang X, Feng M, Felder M, Connor JP, Man YG, Patankar MS, Ho M.
HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy.
J Cancer. 2: 280-91, 2011.
18)  Feng M, Zhang J, Anver M, Hassan R, Ho M.
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice.
J Cancer. 2: 123-31, 2011.
19)  Phung YT, Barbone D, Broaddus VC, Ho M.
Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy.
J Cancer. 2: 507-14, 2011.
20)  Feng M, Kim H, Phung Y, Ho M.
Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro.
Int. J. Cancer. 128: 2246-7, 2011.
21)  Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M.
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
PLoS ONE. 6: e14640, 2011.
22)  Kawa S, Onda M, Ho M, Kreitman RJ, Bera TK, Pastan I.
The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
MAbs. 3: 479-86, 2011.
23)  Gao W, Ho M.
The role of glypican-3 in regulating Wnt in hepatocellular carcinomas.
Cancer Rep. 1: 14-19, 2011.
24)  Pastan I, Ho M.
Recombinant Immunotoxins for Treating Cancer. In: Antibody Engineering. Volume II.
Heidelberg Dordrecht London New York: Springer; 2010. p. 127-146 [Book Chapter]
25)  Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I.
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.
Cancer Res. 70: 1082-9, 2010.
26)  Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, Qian M, Wang XW, Ho M.
Mesothelin as a potential therapeutic target in human cholangiocarcinoma.
J Cancer. 1: 141-9, 2010.
27)  Torisawa Y, Mosadegh B, Cavnar SP, Ho M, Takayama S.
Transwells with Microstamped Membranes Produce Micropatterned Two-Dimensional and Three-Dimensional Co-Cultures.
Tissue Eng Part C Methods. [Epub ahead of print], 2010.
28)  Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, Dimitrov DS.
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
Mol. Cancer Ther. 8: 1113-8, 2009.
29)  Ho M, Pastan I.
Display and selection of scFv antibodies on HEK-293T cells.
Methods Mol. Biol. 562: 99-113, 2009.
30)  Xiao X, Ho M, Zhu Z, Pastan I, Dimitrov DS.
Identification and characterization of fully human anti-CD22 monoclonal antibodies.
MAbs. 1: 297-303, 2009.
31)  Ho M, Pastan I.
In vitro antibody affinity maturation targeting germline hotspots.
Methods Mol. Biol. 525: 293-308, xiv, 2009.
32)  Ho M, Pastan I.
Mammalian cell display for antibody engineering.
Methods Mol. Biol. 525: 337-52, xiv, 2009.
33)  Hassan R, Ho M.
Mesothelin targeted cancer immunotherapy.
Eur. J. Cancer. 44: 46-53, 2008.
34)  Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, Benedict W, Zhang XQ, Lord EM, Litzky LA, Heitjan DF, June CH, Kaiser LR, Vonderheide RH, Albelda SM, Kanther M.
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Clin. Cancer Res. 13: 4456-66, 2007.
35)  Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I.
Mesothelin expression in human lung cancer.
Clin. Cancer Res. 13: 1571-5, 2007.
36)  Du X, Ho M, Pastan I.
New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
J. Immunother. 30: 607-13, 2007.
37)  Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang Q, Ho M, Beers R, Zhao H, Peng P, Zhou J, Li X, Petti G, Janjua A, Liu J, Wu D, Yu D, Zhang Z, Longley C, FitzGerald D, Kreitman RJ, Pastan I.
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Bioconjug. Chem. 18: 773-84, 2007.
38)  Ho M, Nagata S, Pastan I.
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells.
Proc. Natl. Acad. Sci. U.S.A. 103: 9637-42, 2006.
39)  Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Pastan I.
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
Clin. Cancer Res. 12: 4225-31, 2006.
40)  Ho M, Onda M, Wang QC, Hassan R, Pastan I, Lively MO.
Mesothelin is shed from tumor cells.
Cancer Epidemiol. Biomarkers Prev. 15: 1751, 2006.
41)  Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS.
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Mol. Cancer. 5: 50, 2006.
42)  Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, Le N, Ho M, Pastan I.
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice.
Clin. Cancer Res. 12: 4695-701, 2006.
43)  Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A, Pastan IH.
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.
Proc. Natl. Acad. Sci. U.S.A. 102: 7946-51, 2005.
44)  Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I.
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
Clin. Cancer Res. 11: 3814-20, 2005.
45)  Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY.
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
Clin. Cancer Res. 11: 6342-51, 2005.
46)  Ho M, Kreitman RJ, Onda M, Pastan I.
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
J. Biol. Chem. 280: 607-17, 2005.
47)  Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, Hassan R, Kreitman RJ, Pastan I.
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.
Clin. Cancer Res. 11: 5840-6, 2005.
48)  Ho M, Segre M.
Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties.
Biochim. Biophys. Acta. 1638: 257-66, 2003.
49)  Ho M, Segre M.
Cloning and sequence analysis of cDNAs encoding the heavy and light chain variable regions of an Ab2beta anti-idiotypic monoclonal antibody possessing an internal image of cocaine.
Biochim. Biophys. Acta. 1521: 135-40, 2001.
50)  Ho M, Segre M.
Individual and combined effects of ethanol and cocaine on the human dopamine transporter in neuronal cell lines.
Neurosci. Lett. 299: 229-33, 2001.
51)  Ho M, Segre M.
Dopamine uptake by mouse neuroblastoma N1E-115 cells stably expressing human dopamine transporter is differentially inhibited by anti-idiotypic ab2beta antibodies mimicking the configuration of cocaine.
Brain Res. 872: 231-5, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/20/2014.